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Abstract
Background: Extracorporeal Membrane Oxygenation (ECMO) is a technology used in treatment of patients with severe but
potentially reversible respiratory failure. A multi-centre randomised controlled trial (CESAR) was funded in the UK to compare
care including ECMO with conventional intensive care management. The protocol and funding for the CESAR trial included plans
for economic data collection and analysis. Given the high cost of treatment, ECMO is considered an expensive technology for
many funding systems. However, conventional treatment for severe respiratory failure is also one of the more costly forms of
care in any health system.
Methods/Design: The objectives of the economic evaluation are to compare the costs of a policy of referral for ECMO with
those of conventional treatment; to assess cost-effectiveness and the cost-utility at 6 months follow-up; and to assess the cost-
utility over a predicted lifetime. Resources used by patients in the trial are identified. Resource use data are collected from
clinical report forms and through follow up interviews with patients. Unit costs of hospital intensive care resources are based
on parallel research on cost functions in UK NHS intensive care units. Other unit costs are based on published NHS tariffs. Cost
effectiveness analysis uses the outcome: survival without severe disability. Cost utility analysis is based on quality adjusted life
years gained based on the Euroqol EQ-5D at 6 months. Sensitivity analysis is planned to vary assumptions about transport costs
and method of costing intensive care. Uncertainty will also be expressed in analysis of individual patient data. Probabilities of
cost effectiveness given different funding thresholds will be estimated.
Discussion: In our view it is important to record our methods in detail and present them before publication of the results of
the trial so that a record of detail not normally found in the final trial reports can be made available in the public domain.
Trial Registrations: The CESAR trial registration number is ISRCTN47279827.
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Background
Extracorporeal Membrane Oxygenation (ECMO) was
introduced into treatment of severe but potentially revers-
ible respiratory failure in the 1970s. The technique
involves placing patients on a life support circuit with a
membrane oxygenator to temporarily take over the gas
exchange function of e lung thereby allowing the lungs to
rest and recover [1,2]. The early reports of the use of
ECMO in adult with severe respiratory failure were enthu-
siastic [3]. It soon became clear however, that although
ECMO was effective and cost effective compared to con-
ventional ventilation in newborns [4], the evidence was
much less clear for the adult population. Many centres in
the world use ECMO technology and have reported sur-
vival rates in excess of 50% in uncontrolled observational
studies of patient outcomes [5,6]. However, considerable
improvements have also been reported in survival rates of
conventionally treated patients with severe respiratory
failure [7-9].
Given the high cost of treatment, ECMO is considered an
expensive technology for many funding systems. How-
ever, conventional treatment for severe respiratory failure
is also one of the more costly forms of care in any health
system [10]. Differences in lengths of stay and types of
care received by patients following either clinical pathway
may result in different statistical distributions of cost for
inpatient care. In addition, because appropriate care is
provided in relatively few centres, the location of care and
need for specialist transport for patients also affects the
costs of care. Finally, if there is increased survival to dis-
charge from hospital, then there will be more use of serv-
ices in primary and community care, and requirement for
help for recovering people at home. Thus the health serv-
ice costs and the household costs might fall at any stage of
the treatment and recovery, and in many different forms.
In addition to the costs of alternative forms of care, the
economic choice depends on the value of the outcome
gained. Uncertainty about the effectiveness of referral to
an ECMO centre led to a trial to assess the costs and effec-
tiveness of the new form of care funded by the NHS
Health Technology Assessment programme. The protocol
for the 'Conventional ventilation or ECMO for Severe
Adult Respiratory failure (CESAR) Trial was published in
2006 [11]. This paper provides details of the methods
used for the economic evaluation, mentioned in the pro-
tocol and conducted as an integral part of the CESAR trial.
Previous economic evaluations
A literature search failed to find any economic evaluation
studies of adult ECMO. However, there have been a series
of economic evaluations of ECMO in babies alongside the
UK collaborative randomised trial of neonatal ECMO [12]
which reported the estimated additional cost (UK 1994–
95 price) of ECMO per additional surviving infant with no
disability as £75,327 at one year of age. Follow-up at 4
and 7 years for the same study shows the incremental cost
(UK 2001 & 2003 price) of neonatal ECMO to be £24,775
& £23,566 per disability-free life year gained [13,14]. Sim-
ilarly a retrospective cost-utility analysis [15] reports costs
of USD 24,386 per quality adjusted life-year saved for 'sal-
vage ECMO' in children. In all cases, in spite of the high
cost of neonatal ECMO, the incremental cost per QALY
was within health care funders' range of acceptable value
for money. This remains a question in the case of adult
ECMO.
The CESAR Trial
The CESAR trial [11] was designed to compare two alter-
native strategies for treating severe but potentially reversi-
ble respiratory failure: conventional ventilation, and
transfer to a centre providing ECMO. In the UK, during
the CESAR trial, ECMO is provided by Glenfield Hospital,
Leicester, and conventional treatment by other UK hospi-
tals capable of providing a high standard of care for
ECMO eligible patients.
The primary outcome measure for the clinical evaluation
is increase in survival at 6 months without severe disabil-
ity ('confined to bed' and 'unable to wash or dress') at six
months. Power calculations based on estimates of these
outcomes from severe adult respiratory distress syndrome
(ARDS) suggested a sample size of 180 would have suffi-
cient power to detect a reduction in primary outcome by
a third (based on 5% statistical significance, 2-sided test
and 80% power). All ICUs in the UK were invited to take
part in the trial and 148 units referred patients for consid-
eration for entry to the trial. The participation of so many
ICUs is necessary due to the small numbers of adults who
suffer from the condition annually.
Methods
Economic questions about treatment of severe respiratory 
failure
The economic evaluation addresses the question of value
for money of the alternative treatment options. The eco-
nomic question asks "for patients with severe but poten-
tially reversible respiratory failure, is ECMO cost-effective
from the viewpoints of the NHS and society?" This ques-
tion can be rephrased "is the additional cost of achieving
an important gain in outcome within the range that the
health funding system, or society, is willing to pay?"
The objectives of the economic evaluation are:
￿ To compare the costs of a policy of referral for ECMO
with those of conventional treatment.BMC Health Services Research 2008, 8:94 http://www.biomedcentral.com/1472-6963/8/94
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￿ To assess the cost-effectiveness of referral for ECMO
compared with conventional treatment in terms of addi-
tional survival with and without disability at six months
post-randomisation.
￿ To assess the cost-utility of referral for ECMO compared
with conventional treatment in terms of utility gain as
measured by EQ5D at 6 months follow-up.
￿ To assess the cost-utility of referral for ECMO compared
with conventional treatment in terms of utility gain as
measured by EQ5D, and other sources, over a predicted
lifetime.
Design of the Economic Evaluation alongside the CESAR 
Trial
The design of this economic evaluation alongside the
CESAR trial is based on published recommendations [for
example, [16]]. This involves defining: the type of eco-
nomic evaluation to be conducted; the comparator form
of care; the perspective and time horizon for costs and
outcomes; appropriate outcome measures for each per-
spective and type of evaluation; identification, measure-
ment and valuation of resources; estimation of unit costs;
and a plan for economic analysis, which includes deci-
sions on discounting future costs and consequences, tack-
ling uncertainties and presentation of results.
Type of economic evaluation
The first planned analysis is a cost effectiveness analysis
(CEA) with increase in survival without severe disability at
six months (the primary outcome in the CESAR trial) as
the main outcome measure. A short term cost utility anal-
ysis (CUA) was also planned in which health benefits are
quantified in terms of quality-adjusted life-years
(QALYS), and measured using the instrument EQ-5D at 6
months. Lifetime CUA is planned using a decision model
based on CESAR trial results and including additional
data for predicted lifetime QALYs and health care costs.
Comparator
The ideal comparator for any economic evaluation
designed to assess the cost effectiveness in a particular
context is the most commonly used treatment for the con-
dition in that context. The CESAR trial was designed as a
pragmatic comparison, where patients allocated to con-
ventional care were receiving treatment that would be the
normal form of care in the NHS. To ensure that the
patients in the control group received as near as possible
the best practice of care, the CESAR trial protocol specified
aspects of service provision that must be considered,
including facilities available at the participating ICUs,
experience of treating such patients, and certain aspects of
the clinical treatment protocol for ventilated patients. Full
details are given in the CESAR trial protocol [11]. In gen-
eral, however, the comparator group was intended to be
representative of NHS care provision (in qualifying ICUs)
for acute respiratory failure during the period of the trial.
Perspective or viewpoint for analyses
In the UK, the National Institute of Health and Clinical
Excellence (NICE) proposes that applicants presenting
economic analyses for NICE appraisals should take a NHS
perspective [17]. However, there are aspects of public
patient choice and valuation that may not be considered
in such an analysis. Economic evaluators are guided to
take a societal viewpoint if possible [16]. As the ECMO
technology may be adopted for review by NICE or a simi-
lar agency in the UK, it was decided that the perspective
for the CESAR trial should include both the NHS and soci-
etal perspectives. The latter viewpoint is important, as the
results of this study are likely to have economic impacts
other than through health care requirements if there is sig-
nificantly increased survival of either able bodied or disa-
bled adults. It is also anticipated that the results of the trial
may provide useful information for a wider international
audience where different ranges of services are provided
within the health system.
Time horizon for economic evaluation
The follow-up duration for the CESAR trial is 6 months.
This does not allow the full long term cost and benefits to
be measured. However, it satisfies the recommendation of
the American Thoracic Society for cost-effectiveness anal-
yses of ICU therapies to have a minimum follow-up
period of 6 months [10]. However, to meet our fourth
objective, prediction and modelling long-term (lifetime)
costs and benefits are also planned.
Outcome measures for economic evaluation
Survival without severe disability
Death of patients in the trial was recorded during the
period of follow up whenever it occurred. Staff at the
CESAR trial data management centre maintained contact
with all centres with patients being treated within the
CESAR trial ensuring complete reporting. For those dis-
charged from hospital, contact was sought either through
their home, or through their family doctors, if patients
consented to be approached in either of these ways. Any
further deaths would be reported in this way. Severe disa-
bility in survivors at six month was defined as those who
were unable to care for themselves and were confined to
bed: that is who had worst possible scores for the Euroqol
EQ5D domains for self care and for mobility.
Quality adjusted life years (QALYs)
The calculation of QALYs was planned to be based on
assessment of health related quality of life at six months
from randomisation. The EQ-5D is a standardised instru-
ment used for measuring health outcomes. QualityBMC Health Services Research 2008, 8:94 http://www.biomedcentral.com/1472-6963/8/94
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adjusted health utility weights for each patient are calcu-
lated for the CESAR trial using UK specific utility values
for each patient's response to the EQ5D at 6 months. We
could find no previous models for estimation of QALYs
gained at 6 months in similar patients, and so they are
estimated assuming that the value of the health state at
trial entry was zero, and that over the months of survival,
patients have experienced linearly increasing quality of
life up to the level at 6 months.
Estimates of lifetime QALYs are predicted based on
assumptions of gradual improvement of quality of life up
to 2 years from randomization [18-22], and of predicted
life expectancy based on age specific rates for the popula-
tion of England and Wales. Age and sex specific life
expectancy is calculated for each surviving patient in the
trial using UK life tables [23]. It is assumed that, at 24
months post randomization, all surviving trial patients
attained the same average life expectancy and health state
as adults of similar age in the UK population. It is
assumed that average health states for different age groups
would be the same as those obtained from the 1996
Health survey for England [24].
Cost estimation
Identifying resource use
For the CESAR trial relevant aspects of resource use were
identified using expert advice (managers, medical, nurs-
ing and patient representatives all commented on the
draft lists) and also considering the items included in the
economic evaluation of neonatal ECMO [12]. A list of
resource items important from one or more viewpoints is
given in Table 1. This includes resource use associated
with initial stay in intensive and high dependency care
units at different levels of care (measured by number of
organs supported – see below), use of ambulance trans-
port, stays in other hospital wards before discharge, costs
of visiting incurred by relatives whilst patients are in hos-
pital, resource use after discharge up to six months, major
changes in household, out-of-pocket expenses of patient
and family, loss of paid and unpaid working time,
changes in working time, and informal care.
Measuring resource use
Resource use data are collected prospectively for every trial
participant at various points of his/her progress from
recruitment to follow-up using a series of data forms and
questionnaires. Some, but not all, of these are additional
to the instruments planned for the CESAR trial manage-
ment and clinical outcome data collection [11]. These
instruments are:
a) Daily organ support form – completed by intensive care
staff for each trial participant on a daily basis, and used to
classify intensity of resources used during the intensive
care ECMO/conventional treatment period.
b) Transport form (a) at trial entry – completed by Glen-
field Hospital transport team to record transfer of trial par-
ticipants to ECMO centre or conventional treatment
centres.
c) Transport form (b) – completed by Glenfield transport
team to record ambulance journey of participants return-
ing either to the original recruiting hospital or another
intensive care unit after ECMO.
d) Outcomes data sheet – completed by medical staff and
records date on death of patient (if applicable), date of
discharge, date of transfer to another hospital/home, use
of ambulance for transfer etc.
e) Events Diary -to be completed and kept by every partic-
ipant to document all services used from discharge to fol-
low-up as an aide memoire to help them to answer
questions at 6 months. This included information about
informal help received as well as formal services.
f) Patient cost questionnaire at 6 month follow up –
administered by trained interviewer at patient's home or
by telephone to collect resource use data from discharge
to follow-up, covering items recorded in (e) above.
g) GP proforma – completed by GPs to collect medication
use of those patients who refuse the 6-month follow-up
but give permission for use of GP records.
The Events Diary (e) and the Patient cost questionnaire (f)
were piloted with five patients discharged from Glenfield
Hospital ICU, and the GP proforma (g) piloted with 5
general practitioners. Interviewers were trained in the
administration of the patient cost questionnaire (f). As it
was anticipated that many Ambulance Trusts across UK
may become involved in transporting trial patients, all
ambulance trusts were contacted and agreement obtained
to provide costs of patient journeys (including overhead &
running costs) as and when it took place during the trial.
Two items of resource use not collected alongside the trial
are: resource use associated with and following a patient's
death in ICU, and cost incurred by relatives whilst visiting
patients in intensive care/hospital stay. These items were
excluded from the data collection from CESAR trial
patients due to the practical difficulty of collecting data
and due to the lack of a well-defined methodology availa-
ble at the early stages of planning the CESAR trial. How-
ever, the cost of visiting patients in intensive care was
thought likely to be an important social cost, and is being
estimated by a separate study in a sample of CESAR cen-BMC Health Services Research 2008, 8:94 http://www.biomedcentral.com/1472-6963/8/94
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tres and is described in more detail under "estimating unit
costs" below.
Resource data collection for the economic evaluation
Following recruitment, the progress of all participants is
tracked initially until their discharge from hospital so that
resource use, and clinical progress, can be accurately
measured and collected at each stage. During the intensive
treatment period (ECMO or conventional ventilation)
data are collected on number of days spent in each treat-
ment mode, including daily information on number of
organs supported and the level of critical care (ICU or
HDU). After transfer to another hospital or another ward
within the same hospital after the acute phase of the ill-
ness, resource use is measured as number of in-patient
days up to discharge.
Details of all ambulance use related to transferring trial
patients at recruitment are collected by the Glenfield
transport team and details of all other ambulance jour-
neys (for example transfer between hospitals) are col-
lected by the relevant hospitals and sent to the research
team. Data collected include date, time, origin and desti-
nation of journey, mode of transport (road ambulance,
Table 1: Items of resource use in the CESAR trial
Resource items Instrument for data collection within 
CESAR trial
Source of unit cost data References to 
sources
From trail entry to discharge 
from hospital
Days of organ support Daily organ support form ICU costing study [36,37]
Days on ECMO Daily organ support form ICU costing study [36,37]
Days on conventional ventilation Daily organ support form ICU costing study [36,37]
Days in intensive care Daily organ support form ICU costing study [36,37]
Days of other hospital stay before 
discharge
Outcomes data sheet PSSRU – http://www.pssru.ac.uk/uc/
uc2005contents.htm
[25]
Miles transported by air ambulance Transport forms (a) and (b) cost provided by transport provider
Miles transported by land ambulance Transport forms (a) and (b) cost provided by ambulance trusts
From discharge to follow-up at 6 
months
Telephone contacts with GP Events diary and patient cost questionnaire PSSRU [25]
Contacts with NHS direct Events diary and patient cost questionnaire NHS direct personal communication
Visits to GP Events diary and patient cost questionnaire PSSRU [25]
Home visits by nurse Events diary and patient cost questionnaire PSSRU [25]
Visits to counsellor Events diary and patient cost questionnaire PSSRU [25]
Visits to physiotherapist Events diary and patient cost questionnaire PSSRU [25]
Visits to occupational therapist Events diary and patient cost questionnaire PSSRU [25]
Visits by health visitor Events diary and patient cost questionnaire PSSRU [25]
Days of inpatient stay Events diary and patient cost questionnaire PSSRU [25]
Outpatient visits Events diary and patient cost questionnaire PSSRU [25]
A&E visits Events diary and patient cost questionnaire PSSRU [25]
Visits to day hospital/day care Events diary and patient cost questionnaire PSSRU [25]
Days in residential care Events diary and patient cost questionnaire PSSRU [25]
Days in nursing home Events diary and patient cost questionnaire PSSRU [25]
Medication Events diary and patient cost questionnaire PSSRU [25]
Visits by social worker Events diary and patient cost questionnaire PSSRU [25]
Visits by homecare worker Events diary and patient cost questionnaire PSSRU [25]
Aids & adaptations Events diary and patient cost questionnaire Reported by participants and some 
estimated from personal enquiries by 
researcher to equipment suppliers
Value of hours of informal care Events diary and patient cost questionnaire ONS [30]
Miles of private car use for health care Events diary and patient cost questionnaire Automobile Association (AA) [28]
Out-of-pocket expenses Events diary and patient cost questionnaire Reported by CESAR trial patients
Major changes in household Events diary and patient cost questionnaire Reported by CESAR trial patients
Childcare costs Events diary and patient cost questionnaire Reported by CESAR trial patients
Change in employment Events diary and patient cost questionnaire Reported by CESAR trial patients
Change in benefits or allowances Events diary and patient cost questionnaire Reported by CESAR trial patients
Loss of income from employment Events diary and patient cost questionnaire Reported by CESAR trial patients
Other costs Events diary and patient cost questionnaire Reported by CESAR trial patients
Other changes Events diary and patient cost questionnaire Reported by CESAR trial patientsBMC Health Services Research 2008, 8:94 http://www.biomedcentral.com/1472-6963/8/94
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fixed wing aircraft, or helicopter), duration of journey,
and distance travelled by patient.
After discharge from hospital, each participant is sent
details of the forthcoming interview and the 'events diary'
to record resource use. The patient is asked to give permis-
sion for one of a series of options to take place six months
after trial entry: (1) face-to-face interview (2) telephone
interview (3) postal questionnaire and (4) collection of
resource use from GP records. Those patients still in hos-
pital at six months if fit enough are asked to give permis-
sion to be interviewed at their hospital bedside using a
very short resource use questionnaire.
Estimating unit costs
In order to estimate total cost of treatment for each trial
participant, the respective quantities of resource use are
multiplied by their corresponding unit costs. Some
resources used by participants are in the form of actual
costs (not charges) and do not need any valuation. For
example, cost of ambulance journeys are obtained directly
from the relevant ambulance service providers and incor-
porate all overhead and running costs. The unit costs of
most items of resource use are obtained from nationally
available sources [25,26]. Use of medication is valued
using the price of drugs listed in the British National For-
mulary [27]. Informal care is valued by the opportunity
cost method suggested by Posnett & Jan [28]. Average cost
per day of ICU and ECMO is obtained from a separate
study and weighted/adjusted for each centre in the CESAR
trial (see "Cost/day of ICU including ECMO unit care"
below). Cost of visiting is also derived from a separate
study (see "Costs of visiting patients in intensive care"
below). Costs of private travel will be estimated using
Automobile Association (AA) [28] motoring costs.
Valuation of informal care time
Informal time will be valued using weights suggested for
Posnett & Jan's [29] scenarios: working time were output
is replaced; working time where output is not replaced;
non-work time of those in paid employment and those
not in paid employment; and finally time for those not in
paid employment where unpaid housework is not
replaced. Average wage rates of men and women in the
United Kingdom needed for estimating time costs is
obtained from Office of National Statistics (ONS) [30].
Predicted future costs of lifetime care
It was assumed that survivors at 6 months would continue
to have similar average daily costs of care as at the 6
months follow up point, until 24 months post randomi-
zation. At 24 months, the average health service expendi-
ture for the surviving patients in the CESAR trial was
assumed to be the same as that of similar age groups in the
UK. The age groups used in predicting future costs and
benefits were: 16–44 years, 45–64 years, 65–74 years and
75–84 years. Data on health services costs for these age
groups have been published in the proceedings of Parlia-
ment [31]. The same age groups were used as the basis for
estimating both patients' long-term costs and their
benefits.
Price year, inflation, currency and discounting
Resources and costs will be measured in the year in which
they occur using appropriate unit costs for each year of
resource use. All costs are then revalued for analysis and
reporting to 2005 UK values using health care inflation
estimates.
The follow-up duration for the short term analyses is 6
months and therefore discounting is not necessary. For
the lifetime estimates, costs and QALYs were discounted
at 3.5%, based on UK Treasury guidelines [32].
Cost per day of ICU including ECMO unit care
The task of achieving a case-mix adjusted daily costs of
ICU care was achieved through a prospective, observa-
tional, longitudinal multi-centre study (the 'Critical Care
HRG study'), concurrent with the CESAR trial, involving a
volunteer sample of 70 critical care units, where monthly
data on critical care unit expenditure together with daily
data on patients' organ support were collected for a two/
three-month period [33]. The sample of participating crit-
ical care units had good geographical coverage in England
with smaller numbers from Scotland and Northern Ire-
land, but none from Wales. An average daily cost of ICU
was estimated by collecting data on the monthly expend-
iture of intensive care units and apportioning this sum by
their monthly throughput of patients. Case-mix adjust-
ment of this average daily cost was achieved by a weight-
ing based on the number of organs supported on that day.
Data collection
Data on patients' organ support requirements were col-
lected on a daily basis by the critical care unit staff using
specially designed data collection booklets. These data
were collected for consecutive admissions during the
study period. At the same time, the intensive care units
and hospital finance departments were sent question-
naires to document their monthly expenditure on con-
sumables (drugs and fluids, disposable equipment,
nutritional products and blood and blood products), staff
(consultant medical staff and other medical staff), clinical
support services (radiology tests and laboratory services),
professionals allied to medicine (physiotherapists, clini-
cal pharmacists, dieticians, medical technical officers,
information technologists, clinical and biomedical scien-
tists, speech and language therapists, clinical psycholo-
gists and occupational therapists), support staff
(personnel officers and directorate accountants) and spe-BMC Health Services Research 2008, 8:94 http://www.biomedcentral.com/1472-6963/8/94
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cialised bed therapy. Data were also collected on the
organizational characteristics of the intensive care units
and the monthly number of patient days, number of
staffed beds, number of patient admissions etc. An aver-
age daily cost was calculated using the following formula:
The average daily cost in critical care ICU had to be
adjusted to reflect the severity of illness or degree of organ
support required by patients. For this purpose, data pro-
vided by 46 critical care units in the Critical Care ICU
HRG study [34] were used. Only those critical care units
that supplied data on their expenditure, organ support
and unit characteristics were included in this analysis. The
aim was to develop an appropriate model from which
estimates of daily case-mix adjusted costs could be deter-
mined.
Different ways of modelling the organ support and
expenditure data were explored. The model of choice was
informed by the Breusch-Pagan and Hausman specifica-
tion tests [35] that favoured a random-effects model
based on the number of organs supported on a daily basis;
clustered to include 0–1 organ, 2 organs and = 3 organs.
This model offered a simple and reproducible system of
estimating case-mix adjusted costs of care. Daily organ
support weights were 0.577 for 0–1 organ supported,
1.137 for 2 organs supported and 1.156 for = 3 organs
supported [36]. These weights will be applied to average
daily costs of patients participating in the CESAR trial. A
total cost per patient of their ICU stay was calculated by
weighting patients' average daily cost according to the
number of organs supported on a daily basis and sum-
ming these daily costs for each patient.
Internal validation of the average daily cost data collected
was not performed, however external validation was pos-
sible using data collected by the Critical Care National
Cost Block Programme [37]. Twenty-one intensive care
units in this study (30%) contributed data to the Cost
Block Programme for the financial year 2000–2001.
Although the Cost Block Programme collected data for a
different time period and using a different configuration
of units, the similarity between the mean costs per patient
day is striking, in particular, the costs of consumables and
clinical support services. The study by Hibbert et al [33]
had wider coverage of resources with respect to profes-
sionals allied to medicine and an in-built allowance for
capital equipment, which may be responsible for a
slightly higher mean costs per day (£1302, 2003 price
year) compared to £1028 (2001 price year, £1119 inflated
to 2003 price year) for the Cost Block Programme.
The completeness of the returned data was investigated by
each resource item and expressed as a percentage of the
number of responses divided by the total number of 18
possible responses which reflected the quantity of data
sought from participating centres. Data on nursing and
administrative staff together with drugs and fluids yielded
the highest number of responses (77%). Data on clinical
and biomedical scientists and clinical psychologists
yielded the lowest number of responses at 14%.
Not all CESAR centres participated in the Critical Care
HRG study. Separate visits or contacts by correspondence
were made with all CESAR centres that did not participate
in the ICU HRG costing study, including the ECMO cen-
tre, to collect the same expenditure data in order to esti-
mate the daily cost in the same way. Forty hospitals
recruited patients up until the 31st March 2005. Given that
more than one hospital recruited, in some cases, more
than one patient during each financial year and patients
could have received treatment in both an ICU and an
HDU, one hundred and sixteen cost questionnaires were
sent out in total to account for this (58 for the ICU and
combined ICU/High Dependency Units (HDUs) and 58
for the separate HDUs – where provided). The types of
critical care units i.e. which of the participating critical
care units had both an ICU and an HDU or operated as a
combined ICU/HDU, were not known, so each critical
care unit was sent two cost questionnaires for each finan-
cial year when a patient was recruited to the trial. Thirteen
hospitals completed the expenditure questionnaires how-
ever, only 11 hospitals returned data on both their unit
characteristics and expenditure, which were needed in
order to apportion the expenditure data correctly (i.e.
down to an average daily cost). In order to estimate aver-
age daily costs for each CESAR hospital for the financial
year in which a patient/patients were treated, missing data
were substituted with mean estimates obtained from the
responding hospitals by financial year.
Figure 1 shows the whole process of estimating unit costs
of ICU stay, derivation of weights for number of organs
supported and how this feeds into the cost estimation in
the trial. A fuller description of this part of the research is
included in Clare Hibbert's PhD Thesis [36].
Costs of visiting patients in intensive care
A pilot study of the costs of visiting [38] was carried out in
December 2001 at an ICU in the UK. The daily costs per
visit estimated in the pilot study are shown in Table 2. The
pilot study informed the methods for a multi-centre study
in six intensive care units in the UK which are registered
with the CESAR trial. The aim was to estimate the average
cost of visiting patients in intensive care. All adults includ-
ing primary carers visiting the intensive care units during
a three-week duration were requested to complete a ques-
Σ Monthly expenditure on Staff Consumables Clinical Suppor ++ t t Services
Monthly number of patient daysBMC Health Services Research 2008, 8:94 http://www.biomedcentral.com/1472-6963/8/94
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tionnaire that asked them about their time spent in visit-
ing and travel, out-of-pocket expenses, employment
status, loss of income etc. Data from this study will be
used to estimate the average cost of visiting per day.
Analysis and reporting of costs and economic evaluation
Estimation of costs for each patient
Costs falling upon the health sector (health & social serv-
ices), upon patients or their families, and other costs such
as help from friends will be presented in total and disag-
gregated form. Resource use and unit costs described
above will be used for to estimate mean, medians, stand-
ard deviations and ranges of costs for each patient in the
CESAR trial.
Cost effectiveness analysis
Incremental cost-effectiveness ratio (ICER)
With the availability of patient level data on costs and
effects it is possible to summarize uncertainty in the ICER
as a confidence interval. As cost data are typically not nor-
mally distributed, non-parametric bootstrapping will be
used to generate confidence intervals.
Cost utility analysis
Lifetime incremental cost-utility ratios will be estimated
using bootstrap estimation methods [39,40], and using
data and simplifying assumptions described in previous
paragraphs.
Unit cost flowchart for hospital critical care Figure 1
Unit cost flowchart for hospital critical care.
Table 2: Cost of time foregone, lost pay, out-of-pocket expenses per visit to ICU at UK 2005 prices
Daily costs Range (£) Mean (£) Median (£)
Lost pay (n = 5)* 17.36 – 65.10 50.72 54.72
Cost of time foregone (n = 54) 5.04 – 208.32 46.21 24.06
Out-of-pocket expenses 0.00 – 509.54 29.30 9.39
Source: Thalanany et al [38]BMC Health Services Research 2008, 8:94 http://www.biomedcentral.com/1472-6963/8/94
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Sensitivity analysis and uncertainty
Sensitivity analysis based on testing specific assumptions
and probabilistic analysis will be used to explore the
uncertainty in the results [41,42]. Items to be tested in
sensitivity analyses are listed in Table 3. Primary analysis
will be on complete case basis, where a complete case is
defined as cases meeting the CESAR trial clinical effective-
ness data analysis. Estimation of the key cost variables is
based on between 40 and 50 data items representing dif-
ferent aspects of resource use from each participant. If any
single item is missing, the cost variable will also be incom-
plete. We predict that the complete case analysis will con-
tain a small proportion of the total number of trial
participants and thus have a high potential for bias and
imprecision. Any missing resource item values will be
replaced with imputed values and re-analysed as part of
the sensitivity analysis. Missing data will be imputed
using Rubin's multiple imputation method [43] with
SOLAS v3.20 (Statistical Solutions Inc, Co Cork, Eire).
Generalising the results to different settings
It would be beneficial to health care decision makers if
economic study results could be generalised from one set-
ting to another as this would avoid having to repeat every
study in every setting. Factors which may vary in different
settings are: unit costs of resources, geographical varia-
tions in demography or epidemiology of disease, clinical
practice patterns, incentives to health care professionals
and availability of resources. To facilitate estimation of
the transferability of economic data from the CESAR trial
to other health care setting, such factors in the study pop-
ulation will be described, and resource use and prices
reported separately.
Discussion
The CESAR trial is the first RCT of adult ECMO with an
economic evaluation incorporated into the design of the
trial. The CESAR Trial was funded with full economic sup-
port from the design stages of the trial with funding for
two part-time health economists which helped the eco-
nomic research team to tackle many challenges in the
design, methods, data collection, developing and piloting
the economic questionnaire and planning the analysis.
The trial protocol was developed in collaboration with
health economists, who are members of the Trial Steering
Committee, and an economics working group oversees
the economic data collection and analysis.
Incorporation of economic evaluations within ran-
domised controlled trials of medical therapies has been a
growing trend in the past decade. Many health care sys-
tems in developed countries now use economic evalua-
tions as a formal input to decisions about whether to fund
new technologies. In the UK, economic evaluations play a
key role in the technology appraisal process at the
National Institute of Clinical Excellence (NICE) which
makes decisions about a range of health technologies
(NICE 2004).
Economic evaluations conducted alongside randomised
trials are meant to inform decision-makers about the eco-
nomic benefit of the technology under investigation. The
information will shed the most light on the question of
'value for money' if the trial and the evaluation are prop-
erly designed, if appropriate data are collected and cor-
rectly analysed, and if the many sources of uncertainly
surrounding these evaluations are adequately addressed.
The past decade has seen a large increase in the number of
published economic evaluations as well as improvements
in economic evaluation techniques. However, much
debate and confusion still persist among analysts, readers,
and policy- makers concerning methods and the overall
usefulness of CEA in resource allocation decision making.
A number of potential reasons may account for this,
among them political expediency, social preferences and
systemic barriers to implementation. In addition, there
are a number of more technical shortcomings associated
with the generation of economic evidence including
methodological inconsistency across completed eco-
nomic evaluations and the limited generalisability or
transferability of findings or settings beyond the location
of the original study.
The economic evaluation methodology described in this
paper aims to address these issues and guidelines and rec-
ommendations from more recent publications in meth-
Table 3: Items to test during sensitivity analysis
Ranges and thresholds
Days on ECMO Highest & lowest observations
Length of stay in Critical Care Unit (ICU & HDU) Highest & lowest calculated costs
Total length of stay in hospital Highest & lowest calculated costs
Cost per day on organ support Highest & lowest calculated costs
Distance from ECMO centre (cost of transport) Replacing air with road transport
Change in difference in survival Upper & lower CI of the attributable benefit
Other items with significant cost difference Highest & lowest observations
Assumption of linear increasing utility for survivors over first 6 months Assume constant utility at 6 month reported rateBMC Health Services Research 2008, 8:94 http://www.biomedcentral.com/1472-6963/8/94
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ods for economics and trials [44] were used in the design
and conduct of the evaluation and the planned analysis.
The CESAR Trial was funded with full economic support
from the design stages of the trial with funding for three
part-time health economists which helped the economic
research team to tackle many challenges in the design,
methods, data collection, developing and piloting the
economic questionnaire and planning the analysis. The
trial protocol was developed in collaboration with health
economists, who were members of the trial steering
group, and an economics working group including the
trial manager and leaders have overseen the economic
evaluation.
The strengths of the trial on which this economic evalua-
tion was based are that it was randomised and controlled,
pragmatic in design, and provided a vehicle for collecting
a comprehensive set of data on resource use and clinical
effectiveness. These provide a reliable basis for estimating
the economic efficiency of ECMO for adults with severe
respiratory failure. The study cost accounting was compre-
hensive and included most major health service cost
items. Most unit costs used for valuation of reported
resources used were from published national sources and
where unit costs were unavailable rigorous methods were
used for their estimation and the methods used clearly
described. Unit costs for ICU stays were estimated for
every centre that recruited a patient which was then
weighted for each patient to reflect the level of care and
number of organs supported during the acute phase of the
illness. Very few resource items were excluded from the
data collection process alongside the trial.
Presenting this methodology paper before the end of the
trial is an attempt to make transparent the methods used
for the evaluation, and to allay concern of manipulation
of economics results. In our view it is important to record
our methods in detail and present before publication of
the results of the trial so that a record of detail not nor-
mally found in the final trial reports can be made availa-
ble in the public domain.
There are aspects of the planned methods that may be
seen as idealistic. In particular, our estimation of resource
use after hospital discharge is based on patients' reports
after a traumatic period in their lives of many different
aspects of service use and personal costs. The aggregate
cost variables are made up from a combination of this
large number of reported items, many of which may be
missing. Although complete case analysis is our primary
method of analysis, we are conscious that this might be
quite unrepresentative of the CESAR trial population. Our
planned secondary approach is to use imputation of miss-
ing values to increase the numbers of patients for whom
we can estimate costs. However, this also raises the ques-
tion about how much detail we actually needed to collect
from patients (or other sources). Previous researchers
have attempted to establish reduced form resource use
data for costing [45,46] but have not arrived at any general
rules for doing this. Subject to Steering Group approval,
the data from this trial will be available for further analy-
sis of this problem.
Conclusion
As a result of this publication of the methods for the eco-
nomic evaluation in the CESAR trial prior to publication
of the results, we shall be open to scrutiny for any changes
to protocol in our reported data collection and analysis.
By this means we hope to increase confidence in the
results of the economic evaluation.
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